Autoimmune hepatitis.
Michael A Heneghan, Andrew D Yeoman, Sumita Verma...
https://pubmed.ncbi.nlm.nih.gov/23768844Actively Recruiting
Led by University of Milano Bicocca · Updated on 2023-10-11
10000
Participants Needed
1
Research Sites
N/A
Total Duration
Autoimmune Hepatitis (AIH) is a chronic liver disease characterized by ongoing inflammation that can lead to liver failure and the need for transplantation. Both children and adults are affected, with some patients facing reduced life expectancy despite treatment. This study aims to develop a national registry in Italy to better understand the incidence, prevalence, disease progression, and impact of AIH, as well as to assess safety and long-term effects of new therapies. It is an observational, multicenter, retrospective and prospective study focusing on patients older than 1 year. The study will enroll approximately 10,000 AIH patients across Italy over a 120-month period, collecting clinical information, laboratory tests, and biological samples. There is no experimental treatment involved; instead, the study gathers data from patients diagnosed according to recent guidelines. Patients will be followed for a minimum of one year to monitor disease course and outcomes. Participants will provide clinical data and biological samples during the study, with ongoing assessments of liver function and disease activity using various blood tests and liver stiffness measurements. Researchers will track biochemical responses, disease relapse, liver complications requiring hospital admission, and other laboratory indicators over the 11-year study duration. This long-term monitoring will help characterize AIH progression and treatment safety in the Italian population.
CONDITIONS
Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years
Participants who undergo routine care are observed with clinical information and laboratory investigations collected along with biological samples to monitor disease characteristics and progression.
Regular assessments as part of routine healthcare
Duration - Minimum 1 year
Participants are followed for at least 1 year to track disease outcomes, safety, and effectiveness of therapies through ongoing data and sample collection.
Follow-up visits as determined by clinical management
Total: 1 location
1
Fondazione IRCCS San Gerardo dei Tintori
Monza, MB, Italy, 20900
Actively Recruiting
P
Pietro Invernizzi, MD
A
Alessio Gerussi, MD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Michael A Heneghan, Andrew D Yeoman, Sumita Verma...
https://pubmed.ncbi.nlm.nih.gov/23768844Rajani Sharma, Elizabeth C Verna, Jonas Söderling...
https://pubmed.ncbi.nlm.nih.gov/33065308Cara L Mack, David Adams, David N Assis...
https://pubmed.ncbi.nlm.nih.gov/31863477Lin Lee Wong, Holly F Fisher, Deborah D Stocken...
https://pubmed.ncbi.nlm.nih.gov/29663477Simon Pape, Romée J A L M Snijders, Tom J G Gevers...
https://pubmed.ncbi.nlm.nih.gov/35066089Michael A Heneghan, Elizabeth Shumbayawonda, Andrea Dennis...
https://pubmed.ncbi.nlm.nih.gov/35340625Nicole M F van Gerven, Bart J Verwer, Birgit I Witte...
https://pubmed.ncbi.nlm.nih.gov/22989569